PT788480E - Cristalizacao de levobupivacaina e seus analogos - Google Patents

Cristalizacao de levobupivacaina e seus analogos

Info

Publication number
PT788480E
PT788480E PT95934738T PT95934738T PT788480E PT 788480 E PT788480 E PT 788480E PT 95934738 T PT95934738 T PT 95934738T PT 95934738 T PT95934738 T PT 95934738T PT 788480 E PT788480 E PT 788480E
Authority
PT
Portugal
Prior art keywords
pct
levobupivacaine
analogs
crystallization
sec
Prior art date
Application number
PT95934738T
Other languages
English (en)
Inventor
Marianne Langston
Benjamin Mark Skead
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421476A external-priority patent/GB9421476D0/en
Priority claimed from GBGB9504926.8A external-priority patent/GB9504926D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of PT788480E publication Critical patent/PT788480E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
PT95934738T 1994-10-25 1995-10-23 Cristalizacao de levobupivacaina e seus analogos PT788480E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421476A GB9421476D0 (en) 1994-10-25 1994-10-25 Process and salt
GBGB9504926.8A GB9504926D0 (en) 1995-03-10 1995-03-10 Crystallisation

Publications (1)

Publication Number Publication Date
PT788480E true PT788480E (pt) 2003-12-31

Family

ID=26305863

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95934738T PT788480E (pt) 1994-10-25 1995-10-23 Cristalizacao de levobupivacaina e seus analogos

Country Status (16)

Country Link
US (1) US5994548A (pt)
EP (1) EP0788480B1 (pt)
JP (1) JP3911545B2 (pt)
AT (1) ATE245629T1 (pt)
AU (1) AU698637B2 (pt)
CA (1) CA2200355C (pt)
DE (1) DE69531356T2 (pt)
DK (1) DK0788480T3 (pt)
ES (1) ES2202375T3 (pt)
FI (1) FI117438B (pt)
HU (1) HU227420B1 (pt)
MX (1) MX9703024A (pt)
NO (1) NO309266B1 (pt)
PL (1) PL183210B1 (pt)
PT (1) PT788480E (pt)
WO (1) WO1996012699A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US7094812B2 (en) * 2003-04-24 2006-08-22 Xerox Corporations Colorant compositions
US6790267B1 (en) * 2003-04-24 2004-09-14 Xerox Corporation Colorant compositions
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007123405A1 (en) * 2006-04-25 2007-11-01 Dishman Pharmaceuticals And Chemicals Ltd. Ropivacaine hydrochloride anhydrate and the preparation thereof
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
ES2383714T3 (es) * 2008-01-15 2012-06-25 Pharmathen S.A. Proceso para preparar un compuesto (S)-1-alquil-2',6'-pipecoloxilidídico
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN103073484B (zh) * 2013-01-28 2014-10-22 山东诚创医药技术开发有限公司 一种甲哌卡因及其光学对映体的制备方法
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
CA3048485C (en) * 2016-12-26 2022-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE341404B (pt) * 1967-05-18 1971-12-27 Sterling Drug Inc
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
AU3704895A (en) 1996-05-15
JP3911545B2 (ja) 2007-05-09
HUT77631A (hu) 1998-06-29
PL319829A1 (en) 1997-09-01
JPH10507464A (ja) 1998-07-21
DK0788480T3 (da) 2003-09-29
FI117438B (fi) 2006-10-13
MX9703024A (es) 1997-10-31
HU227420B1 (en) 2011-05-30
WO1996012699A1 (en) 1996-05-02
FI971711A0 (fi) 1997-04-22
CA2200355A1 (en) 1996-05-02
FI971711L (fi) 1997-04-22
AU698637B2 (en) 1998-11-05
EP0788480A1 (en) 1997-08-13
PL183210B1 (pl) 2002-06-28
DE69531356T2 (de) 2004-05-27
US5994548A (en) 1999-11-30
NO971903D0 (no) 1997-04-24
EP0788480B1 (en) 2003-07-23
DE69531356D1 (de) 2003-08-28
NO309266B1 (no) 2001-01-08
NO971903L (no) 1997-04-24
ES2202375T3 (es) 2004-04-01
ATE245629T1 (de) 2003-08-15
CA2200355C (en) 2007-03-06

Similar Documents

Publication Publication Date Title
NO971903D0 (no) Krystallisering av levobupivacain og analoger derav
DE59308619D1 (de) Germicide wirkstoffkombinationen
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
DK0581959T3 (da) Anvendelse af makrolidforbindelser til øjensygdomme
DK393288D0 (da) Praeparat til saarheling og knogleregenerering
DE59100830D1 (de) Verfahren zur Herstellung von 3-Aminomethyl-3,5,5,-trimethyl-cyclohexylamin.
DE59209922D1 (de) Thrombin sowie Verfahren zu seiner Herstellung
ATE57176T1 (de) Verfahren zur herstellung von (2,2)-paracyclophan und dessen abkoemmlinge.
ATE153022T1 (de) 3',5'-ditertbutyl-4'-hydroxyflavone, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung mit antioxidations- und antivasokonstriktionsaktivität
DE69109401D1 (de) Wässrige Zusammensetzungen zur Behandlung von porösen Substraten.
TR26748A (tr) SU VE N-METIL-MORFOLIN-N-OKSIT ICINDE SELüLOZ CÖZELTISI.
ATE89561T1 (de) 3,4-disubstituierte-2-azetidinon-derivate und verfahren zu ihrer herstellung.
DE3887197D1 (de) Verfahren zur Herstellung von Glucosedehydrogenase aus Bacillus megaterium.
DE59105224D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolidonen.
FI954138A0 (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
DE59407675D1 (de) Verfahren zur Herstellung von 6H-Dibenz-(c,e)(1,2)-oxaphosphorin-6-on
PT806206E (pt) Composicoes aquosas que contem ciprofloxacina e utilizacao e processo correspondentes
DE69103913D1 (de) Verfahren zur Herstellung von Dodekandicarbonsäure.
SE8206548L (sv) Bensylidenderivat
ATE73136T1 (de) Verfahren zur herstellung von 6alpha, 9alphadifluor-11beta, 17alpha-dihydroxy-16alpha-methyl4-pregnen-3,20-dion und dessen derivate.
ATE84780T1 (de) Neue di(meth)acrylate, verfahren zu deren herstellung und deren verwendung.
DE68924316D1 (de) Menschliches Gamma-Interferon, Verfahren zu seiner Herstellung und seine Verwendung.
DE3764330D1 (de) 2,2;6,6-diethylen-3-oxo-17alpha-pregn-4-en-21, 17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharm. praeparate.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE3750747D1 (de) Chemische Behandlung von Likören.